Kala Bio (KALA) Current Leases (2017 - 2025)
Kala Bio (KALA) posted Current Leases of $420000.0 for Q3 2025, up 3.45% sequentially from $406000.0 in Q2 2025, and up 14.13% YoY from $368000.0 in Q3 2024.
Kala Bio (KALA) Current Leases (2017 - 2025) Analysis & Trends
Kala Bio has reported Current Leases for 9 years, with the latest figure at $420000.0 in Q3 2025.
- Quarterly Current Leases rose 14.13% year-over-year to $420000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $420000.0 (up 14.13% YoY) and the FY2024 annual result came in at $380000.0, up 13.77% from the prior year.
- Current Leases rose to $420000.0 in Q3 2025 per KALA's latest filing, from $406000.0 in the prior quarter.
- Over five years, Current Leases peaked at $2.0 million in Q1 2021 and troughed at $3000.0 in Q1 2023.
- A 5-year average of $589388.9 and a median of $374000.0 in 2024 frame the typical range for Current Leases.
- The sharpest annual moves came in 2023 and 2024: Current Leases slumped 99.52% in 2023, then surged 11400.0% in 2024.
- Over 5 years, Current Leases stood at $711000.0 in 2021, then sank by 98.17% to $13000.0 in 2022, then surged by 2469.23% to $334000.0 in 2023, then grew by 13.77% to $380000.0 in 2024, then advanced by 10.53% to $420000.0 in 2025.
- According to Business Quant data, Current Leases over the past three periods registered $420000.0, $406000.0, and $393000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | - |
| 10 | Kala Bio | 9.97 Mn | 9.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 420,000.00 |
| Jun 30, 2025 | 406,000.00 |
| Mar 31, 2025 | 393,000.00 |
| Dec 31, 2024 | 380,000.00 |
| Sep 30, 2024 | 368,000.00 |
| Jun 30, 2024 | 356,000.00 |
| Mar 31, 2024 | 345,000.00 |
| Dec 31, 2023 | 334,000.00 |
| Sep 30, 2023 | 324,000.00 |
| Mar 31, 2023 | 3,000.00 |
| Dec 31, 2022 | 13,000.00 |
| Sep 30, 2022 | 32,000.00 |
| Jun 30, 2022 | 52,000.00 |
| Mar 31, 2022 | 625,000.00 |
| Dec 31, 2021 | 711,000.00 |
| Sep 30, 2021 | 1.89 Mn |
| Jun 30, 2021 | 1.98 Mn |
| Mar 31, 2021 | 1.99 Mn |
| Dec 31, 2020 | 1.53 Mn |
| Sep 30, 2020 | 1.48 Mn |